Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 89 EV-to-EBITDA is 13.05 as of Aug. 25, 2026, which is 33% above its 10-year median of 9.81. GuruFocus rates LJUIF with a GF Score™ of 89/100 and a GF Value™ of $0.49. The stock has 7 warning signs investors should review. Among 735 Drug Manufacturers companies, SSY Group ranks better than 50.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SSY Group's enterprise value is $1,240.4 Mil.
SSY Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $95.1 Mil. Therefore, SSY Group's EV-to-EBITDA for today is 13.05.
The historical rank and industry rank for SSY Group's EV-to-EBITDA or its related term are showing as below:
LJUIF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.74 Med: 9.81 Max: 25.43
Current: 13.08
During the past 13 years, the highest EV-to-EBITDA of SSY Group was 25.43. The lowest was 5.74. And the median was 9.81.
LJUIF's EV-to-EBITDA is ranked better than 50.2% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.46
vs LJUIF: 13.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SSY Group's share price for today is $0.40255.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SSY Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SSY Group's EV-to-EBITDA falls into.
SSY Group's current Enterprise Value is $1,240.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $95.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a EV-to-EBITDA of 13.05 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SSY Group. This is 33% above median its historical median of 9.81. Over the past decade, SSY Group's EV-to-EBITDA has ranged from 5.74 to 25.43. According to the industry distribution chart, SSY Group ranks #366 out of 735 companies in the Drug Manufacturers industry, placing it in the top 49.8%.
Is SSY Group's EV-to-EBITDA too high?
SSY Group's current EV-to-EBITDA of 13.05 is 33% above median its 10-year median of 9.81. Over the past 10 years, this metric has ranged from a low of 5.74 to a high of 25.43. The Drug Manufacturers industry median EV-to-EBITDA is 13.46. SSY Group's value of 13.05 is 3% below this industry median. Based on the distribution chart, SSY Group ranks #366 out of 735 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SSY Group has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #366 out of 735 companies for EV-to-EBITDA. This puts SSY Group in the upper half of its industry. The industry median EV-to-EBITDA is 13.46. SSY Group's value of 13.05 is 3% below this benchmark. Historically, SSY Group's own EV-to-EBITDA has ranged from 5.74 to 25.43 over the past decade. While the company's 10-year median is 9.81 vs. the industry median of 13.46, SSY Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.46, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current EV-to-EBITDA of 13.05 is 3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SSY Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current EV-to-EBITDA is 13.05, which is 33% above median its own 10-year median of 9.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current EV-to-EBITDA of 13.05. The stock's GF Value™ is $0.49, compared to a current price of $0.40 — trading 17.8% below its estimated fair value. The current EV-to-EBITDA is 13.05, which is 33% above median its 10-year median of 9.81 and 3% below the Drug Manufacturers industry median of 13.46. SSY Group's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SSY Group (LJUIF), the current EV-to-EBITDA is 13.05 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 17.8% below its estimated GF Value™ of $0.49.
Key valuation signals for LJUIF:
EV-to-EBITDA: 13.05 (33% above median its 10-year median of 9.81)
GF Value™: $0.49 vs. price of $0.40 (17.8% below fair value)
Industry Position: 3% below the Drug Manufacturers median (#366 of 735)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
89GF Score
Get the complete analysis for LJUIF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
